• 1
    Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993; 167: 12471251.
  • 2
    Edwards JE Jr. Invasive Candida infection: evolution of a fungal pathogen. N Engl J Med. 1991; 324: 10601062.
  • 3
    Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29: 239244.
  • 4
    Bodey GP. Hematogenous and major organ candidiasis. In: BodeyGP, editor. Candidiasis: pathogenesis, diagnosis, and treatment (2nd edition). New York: Raven Press, 1993: 279329.
  • 5
    Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992; 15: 414421.
  • 6
    Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002; 359: 11351144.
  • 7
    Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002; 23: 542545.
  • 8
    Nguyen MH, Peacock JE Jr., Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100: 617623.
  • 9
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J Infect Dis. 2000; 181: 309318.
  • 10
    Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997; 24: 11221128.
  • 11
    Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 2003; 36: 12211228.
  • 12
    Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331: 13251330.
  • 13
    Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002; 21: 767774.
  • 14
    Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multi-center surveillance study by the Invasive Fungal Infection Group B (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999; 28: 10711079.
  • 15
    Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997; 16: 337345.
  • 16
    Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Am J Med. 1981; 71: 363370.
  • 17
    Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore). 2002; 81: 425433.
  • 18
    Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2000; 19: 602607.
  • 19
    Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003; 37: 634643.
  • 20
    Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial candidemia. Diagn Microbiol Infect Dis. 2002; 44: 353357.
  • 21
    Guerra-Romero L, Telenti A, Thompson RL, Roberts GD. Polymicrobial fungemia: microbiology, clinical features, and significance. Rev Infect Dis. 1989; 11: 208212.
  • 22
    Johnson MD, Gottfredsson M, Perfect JR. Polyfungemia at a tertiary care medical center 1992-2001: a decade of experience [abstract]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27–30, 2002.
  • 23
    Larone DH. Medically important fungi: a guide to identification. Washington, DC: American Society for Microbiology Press, 2002.
  • 24
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818829.
  • 25
    Ahmad S, Khan Z, Mustafa AS, Khan ZU. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol. 2002; 40: 24832489.
  • 26
    Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol. 1994; 32: 19231929.
  • 27
    Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003; 82: 309321.
  • 28
    Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis. 2001; 33: 16761681.
  • 29
    Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998; 104: 238245.